Zolmitriptan is absolutely contraindicated in this patient and should not be taken.
A patient with a history of NSTEMI has established ischemic coronary artery disease, which is an absolute contraindication to zolmitriptan use according to the FDA drug label 1. The presence of infective endocarditis adds additional cardiovascular risk but the prior NSTEMI alone is sufficient to prohibit zolmitriptan use.
Why Zolmitriptan is Contraindicated
The FDA explicitly contraindicates zolmitriptan in patients with:
- Ischemic coronary artery disease (including history of myocardial infarction)
- Documented silent ischemia
- Coronary artery vasospasm 1
This patient's NSTEMI history definitively establishes ischemic heart disease, making zolmitriptan use dangerous regardless of the infective endocarditis.
Mechanism of Risk
Zolmitriptan is a 5-HT1B/1D receptor agonist that causes coronary artery vasoconstriction 1. In patients with underlying coronary disease:
- It can precipitate coronary vasospasm (Prinzmetal's angina) even without significant CAD 1
- Multiple case reports document acute myocardial infarction following zolmitriptan use 2, 3, 4
- Serious cardiac events can occur within hours of administration 1
Additional Cardiovascular Concerns
The combination of infective endocarditis and prior NSTEMI creates a particularly high-risk cardiovascular profile:
- Active endocarditis can cause septic coronary embolism leading to acute MI 5, 6
- Patients with IE and reduced LVEF require beta-blockers and ACE inhibitors 7, 8
- Any vasoconstrictive agent poses unacceptable risk in this already compromised cardiovascular state
Alternative Migraine Management
For this patient, migraine treatment options should include:
- Non-triptan acute therapies: NSAIDs (if no contraindication), acetaminophen, antiemetics
- Preventive therapy: Beta-blockers (which are already indicated for the NSTEMI history with LVEF ≤40% 7, 8)
- Other acute options: Consider consultation with neurology for non-vasoconstrictive alternatives
All triptan medications share similar contraindications due to their vasoconstrictive mechanism 9, so alternative triptans are equally contraindicated.
Critical Clinical Pitfall
Do not assume that because the NSTEMI occurred in the past, the contraindication no longer applies. The FDA contraindication specifically includes "history of myocardial infarction" 1, making this a permanent contraindication unless the patient undergoes comprehensive cardiovascular evaluation demonstrating complete resolution of ischemic disease—which is rarely the case.